FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 361:403-405 July 23, 2009 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Sur, D. PubMed Citation

Enteric fevers encompass typhoid fever caused by Salmonella enterica serotype Typhi (S. Typhi) and paratyphoid fever caused by serotype Paratyphi A or B (S. Paratyphi). These human-restricted pathogens are acquired by ingesting contaminated water or food, and in the individual patient, one cannot differentiate clinically which agent is causing illness. S. Typhi expresses a capsular "Vi" (for virulence) polysaccharide, whereas S. Paratyphi A and B cannot synthesize Vi.

Before the use of antibiotics, typhoid fever had a case fatality rate of 10 to 20%. Transmission of enteric fever is minimized or eliminated if populations . . . [Full Text of this Article]

Source Information

From the Center for Vaccine Development, University of Maryland School of Medicine, Baltimore.

Related Letters:

A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India
Arya S. C., Agarwal N., Schwartz E., Clemens J., Sur D., Ochiai R. L., Levine M. M.
Extract | Full Text | PDF  
N Engl J Med 2009; 361:2191-2193, Nov 26, 2009. Correspondence

This article has been cited by other articles:

• Arya, S. C., Agarwal, N., Schwartz, E., Clemens, J., Sur, D., Ochiai, R. L., Levine, M. M. (2009). A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.. NEJM 361: 2191-2192 [Full Text]  
• (2009). Vi Typhoid Vaccine Trial. JWatch Infect. Diseases 2009: 1-1 [Full Text]